Research
Hormonal
GLP-1 receptor agonists decrease weight in people with schizophrenia.
GLP-1 receptor agonists may be considered as a treatment option for weight management in patients with schizophrenia.
StrongSupportsmedium confidence
Results from completed trials suggest that GLP-1RAs decrease weight in people with schizophrenia.
Why this rating
Based on the completion of multiple clinical trials.
Source
GLP-1 receptor agonists and weight loss in schizophrenia – past, present, and future
Mike Trott et al. · Current Opinion in Psychiatry · 2024
DOI 10.1097/yco.0000000000000952
reviewCited 16×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →